FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-2222.4%−1815.0 pts over 5 years
Net margin
-2051.1%−1499.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -51.2% | -59.0% | -26.7% | +10.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -60.2% | -55.1% | -51.8% | |
| Return on assets | -41.1% | -37.5% | -35.9% | |
| Current ratio | 6.14 | 5.78 | 5.79 | |
| Debt to equity | 0.15 | – | – | |
| Net debt to EBITDA | 2.51× | – | – | |
| Interest coverage | -19.5× | – | – | |
| Capex to revenue | 10.4% | 15.7% | 89.6% | |
| Diluted shares | 32M | 82M | 119M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Fate Therapeutics generated $772.30M from operations and spent $99.11M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$772.30M
Used
$99.11M
Capital expenditure$99.11M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2051.1%
×Asset turnover0.02×
×Equity multiplier1.44×
=Return on equity, FY2025-51.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -2051.1% | 0.02× | 1.44× | -51.8% |
| FY2024 | -1366.5% | 0.03× | 1.38× | -54.2% |
| FY2023 | -253.3% | 0.10× | 1.42× | -37.8% |
| FY2022 | -292.5% | 0.12× | 1.40× | -48.5% |
| FY2021 | -379.9% | 0.07× | 1.45× | -39.9% |
| FY2020 | -551.6% | 0.07× | 1.47× | -55.1% |
| FY2019 | -919.0% | 0.04× | 1.27× | -48.4% |
| FY2018 | -1405.0% | 0.03× | 1.34× | -56.0% |
| FY2017 | -1046.1% | 0.04× | 1.33× | -57.1% |
| FY2016 | -760.2% | 0.05× | 1.47× | -60.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$136.32M
- Cash generatingOperating cash flow above zero-$106.08M
- Return on assets improvedROA up on the prior year-36.8% → -30.9%
- Earnings backed by cashOperating cash flow above net income-$106.08M vs -$136.32M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.58 → 5.79
- No dilutionShare count did not rise114M → 119M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.03 → 0.02